samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Analytical Toolbox for Cell and Gene Therapy development

Protagen Protein Services



Gene therapies play an increasingly significant role in the future of medicine. Process development and quality testing are yet in the focus of the international authorities. Today, due to their specific characteristics as non self-replicative viral vectors, adeno-associated viruses (AAVs) are a safe approach for delivering the genes of interest.

Innovative companies face analytical challenges to find the most effective ways of process development and standardization. There is a broad range of important quality attributes for delivery vectors which need to be closely controlled for efficacy and biosafety of gene therapy. PPS has established specialized testing packages for the characterization and quality control testing of AAV particles and constituent capsid protein assemblies.

Adeno-associated viruses – benefits and challenges

AAV based gene therapy is driving today’s therapeutic discoveries and has evolved to the leading strategy for the treatment of genetic diseases. Simultaneously, the regulatory demands are increasing and authorities request extensive analytical characterization for the drug vectors (e.g. capsid loading, process impurities). Hence, reliable, robust, GMP-compliant analytical methods and characterization protocols are required. Specific analytical assays need to be performed to assess vector productivity, vector purity, biological activity and safety.

Adeno-associated viruses – benefits and challenges

AAV based gene therapy is driving today’s therapeutic discoveries and has evolved to the leading strategy for the treatment of diseases. Simultaneously, the regulatory demands are increasing and authorities request extensive analytical characterization for the drug vectors (e.g., capsid loading, process impurities). Hence GMP-compliant analytical methods and characterization protocols are required. To assess vector productivity, vector purity, biological activity and safety various analytical assays need to be performed.

Analytical toolbox

Based on more than 20 years of analytical, biopharmaceutical experience, we can address our clients’ specific needs by swift and effective analytical support throughout the whole lifecycle of their gene therapy products and development processes. As a full-service partner PPS offers a broad range of analytical methods to quantify the strength/dose of the AAV vector, to quantify full and empty particles as well as particles carrying wrongly encapsulated DNA. Therefore, our analytical platform enables us to ensure the identity, purity, potency, and safety of the final product. To prove whether the gene of interest is present in the vector is essential for surveilling the production process as well as for the evaluation of the right dosage for the patient.

As a very common example - PPS can provide information on vector loading using several techniques:

  • Analytical ultracentrifugation (AUC)
  • Size-exclusion chromatography combined with multiangle laser light scattering (SEC-MALLS)
  • Capillary gel electrophoresis assay (cGE)
  • Ion exchange chromatography (IEX)
AUC analysis in particular can be integrated in existing processes to detect vector loading at particular steps in manufacturing and by that constributes to the quality of the final product.

Figure 1: Analysis of capsid loading of AAVs using Analytical Ultracentrifugation (AUC)

„Quality control of adeno-associated virus preparations can be a very complex matter in respect to the viral vector/serotype or the formulation compounds“, says Dr. Stefan Haberland, Teamleader Biotherapeutical Analytics. „We use analytical ultracentrifugation not only to analyze the relative amounts of filled and empty capsids in an AAV preparations, but also to identify partially filled and overpackaged species.

SEC-MALLS allows testing several critical quality attributes of an AAV product. „Our SEC-MALLS platform provides data to measure different parameters within one single run, such as molecular weight, capsid-particle concentration and empty-to-full ratio. They can easily be implemented into the established production processes as an orthogonal and complementary approach that offers data validation throughout the whole AAV production process. An indispensable and time-saving tool for AAV manufacturing, quality control, and assurance of regulatory aspects“, he explaines.

 
Quality control along the entire development and production pathway

By means of our comprehensive portfolio we support the development and execution of cell- and gene therapy programs from basic research through to the clinical stage by providing innovative, safe and GMP-compliant CMC testing. Our technology ensures the safe and reliable analysis of identity, potency, purity, and safety of starting materials, intermediate products, vectors and final drug products as well as support for manufacturing process development and validation.

From mass spectrometry (in vivo cQA mapping, peptide mapping, molecular weight determination, glycan profiling) through to higher order analysis (DLS, DSC) and analytical testing (e.g., AUC, LC-MS, HPLC, ELISA and qPCR methods, UPLC)
phone +49 231 9742 61 00
email contact@protagenproteinservices.com
web www.protagenproteinservices.com
email Protagen Protein Services (GmbH), Inselwiesenstraße 10, D-74076 Heilbronn
 
Print this page
Send to a friend
   
spacer
News and Press Releases

European Medicines Agency Begins Rolling Review of Moderna’s mRNA Vaccine Candidate Against COVID-19 (mRNA-1273)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 17, 2020-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the European Medicines Agency (EMA) human medicines committee (CHMP) has started a rolling review of mRNA-1273, the Company’s vaccine candidate against COVID-19, following the confirmation of eligibility of mRNA-1273 for submission on October 14, 2020.
More info >>


White Papers

Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring

Dycem

A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement